SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

      Date of Report (date of earliest event reported): September 20, 2010

                           EFT BIOTECH HOLDINGS, INC.
                  ------------------------------------------
                 (Name of Small Business Issuer in its charter)

           Nevada                      0-53730               20-1211204
 ------------------------     ---------------------       -------------------
 (State of incorporation)     (Commission File No.)        (IRS Employer
                                                          Identification No.)

                         17800 Castleton St., Suite 300
                           City of Industry, CA 91748
                ---------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (626) 581-3335

                                       N/A
               -------------------------------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
   Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-14(c) under the
   Exchange Act (17 CFR 240.13e-4(c))



<PAGE>

Item 5.02  Departure of Directors or Certain  Officers;  Election of  Directors;
Appointment of Certain officers; Compensatory Arrangements of Certain Officers.


     On September 20, 2010 Jack Jie Qin was appointed as the Company's principal
accounting  officer.  Mr. Qin is the Company's president and principal executive
and  financial  officer.  Information  regarding  Mr.  Qin can be  found  in the
Company's  report on form 10-K for the year ended March 31, 2010.  The Company's
10-K report is  available  to the public  through the website of the  Securities
Exchange Commission (www.sec.gov).

Item 8.01   Other Events.

     Between  January and August of 2008 the Company  sold  14,890,040  Units to
non-U.S. residents at a price of $3.80 per Unit. The Units were sold pursuant to
the  exemption   provided  by  Regulation  S  of  the  Securities  and  Exchange
Commission.

     Each Unit  consisted  of one share of the  Company's  common  stock and one
warrant. Each warrant allows the holder to purchase one share of the Company's
common stock at a price of $3.80.

     The expiration date of the warrants has been extended to November 30, 2011.

                                       2
<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:   September 22, 2010                EFT BIOTECH HOLDINGS, INC.



                                          By:  /s/ Jack Jie Qin
                                              -----------------------
                                              Jack Jie Qin, President
[{"type": "8-K", "sequence": "1", "filename": "form8kitem5029-10.txt", "description": "8-K RE ITEM 5.02 9-10", "secsgml_size_bytes": 3718}]
{"company-data": {"conformed-name": "EFT BIOTECH HOLDINGS INC", "cik": "0001450973", "assigned-sic": "5990", "irs-number": "770719310", "state-of-incorporation": "NV", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-53730", "film-number": "101086289"}, "business-address": {"street1": "929 RADECK CT", "city": "CITY OF INDUSTRY", "state": "CA", "zip": "91748", "phone": "626 581 0388"}, "mail-address": {"street1": "929 RADECK CT", "city": "CITY OF INDUSTRY", "state": "CA", "zip": "91748"}}
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

      Date of Report (date of earliest event reported): September 20, 2010

                           EFT BIOTECH HOLDINGS, INC.
                  ------------------------------------------
                 (Name of Small Business Issuer in its charter)

           Nevada                      0-53730               20-1211204
 ------------------------     ---------------------       -------------------
 (State of incorporation)     (Commission File No.)        (IRS Employer
                                                          Identification No.)

                         17800 Castleton St., Suite 300
                           City of Industry, CA 91748
                ---------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (626) 581-3335

                                       N/A
               -------------------------------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
   Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-14(c) under the
   Exchange Act (17 CFR 240.13e-4(c))
Item 5.02  Departure of Directors or Certain  Officers;  Election of  Directors;
Appointment of Certain officers; Compensatory Arrangements of Certain Officers.

     On September 20, 2010 Jack Jie Qin was appointed as the Company's principal
accounting  officer.  Mr. Qin is the Company's president and principal executive
and  financial  officer.  Information  regarding  Mr.  Qin can be  found  in the
Company's  report on form 10-K for the year ended March 31, 2010.  The Company's
10-K report is  available  to the public  through the website of the  Securities
Exchange Commission (www.sec.gov).

Item 8.01   Other Events.

     Between  January and August of 2008 the Company  sold  14,890,040  Units to
non-U.S. residents at a price of $3.80 per Unit. The Units were sold pursuant to
the  exemption   provided  by  Regulation  S  of  the  Securities  and  Exchange
Commission.

     Each Unit  consisted  of one share of the  Company's  common  stock and one
warrant. Each warrant allows the holder to purchase one share of the Company's
common stock at a price of $3.80.

     The expiration date of the warrants has been extended to November 30, 2011.

                                       2
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:   September 22, 2010                EFT BIOTECH HOLDINGS, INC.

                                          By:  /s/ Jack Jie Qin
                                              -----------------------
                                              Jack Jie Qin, President